Testing New Treatments to Block Inflammation in MS

Dr Iain Comerford

University of Adelaide, SA

| Better treatments | Immunology | Project | 2023 | Investigator Led Research |


In multiple sclerosis (MS), cells of the immune system invade the brain and spinal cord and cause tissue damage that leads to loss of function of the nervous system. A specific class of T cells, a type of immune cell that are strongly implicated in MS, are recruited to the brain and spinal cord. Why this happens is not fully understood.  Potential new treatments include drugs that can block migration of the immune cells that promote inflammation.  

Disease-modifying therapies (DMTs) that inhibit T cell recruitment for MS target T cells may have off-target effects on other aspects of the immune system. Strategies that specifically control pathogenic T cell migration have yet to be identified. 

In this project, Dr Iain Comerford and his team will investigate the role of three proteins that they believe work together to promote recruitment of inflammatory cells into the brain. They will do this by generating models of MS lacking these proteins to determine the effect of this on an MS-like disease. 

Updated: 22 February, 2023

Stages of the research process

Fundamental laboratory

Laboratory research that investigates scientific theories behind the possible causes, disease progression, ways to diagnose and better treat MS.

Lab to clinic timeline: 10+ years

Research that builds on fundamental scientific research to develop new therapies, medical procedures or diagnostics and advances it closer to the clinic.

Lab to clinic timeline: 5+ years
Clinical Studies
and Clinical Trials

Clinical research is the culmination of fundamental and translational research turning those research discoveries into treatments and interventions for people with MS.

Lab to clinic timeline: 1-5 years


Dr Iain Comerford 

Total Funding

  • $246,953


  • 3 years – starting 2023

Read More

Newsletter subscription

  • Enter your details

Testing New Treatments to Block Inflammation in MS